

AD_____

Award Number: DAMD17-03-1-0429

TITLE: Proteomic Analysis to Identify Novel Circulating Breast
Cancer Markers

PRINCIPAL INVESTIGATOR: Francisco J. Esteve, M.D., Ph.D.

CONTRACTING ORGANIZATION: University of Texas M.D. Anderson Cancer
Center
Houston, Texas 77030

REPORT DATE: June 2004

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are
those of the author(s) and should not be construed as an official
Department of the Army position, policy or decision unless so
designated by other documentation.

20040917 093

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)			2. REPORT DATE June 2004		3. REPORT TYPE AND DATES COVERED Annual (27 May 2003 - 26 May 2004)	
4. TITLE AND SUBTITLE Proteomic Analysis to Identify Novel Circulating Breast Cancer Markers			5. FUNDING NUMBERS DAMD17-03-1-0429			
6. AUTHOR(S) Francisco J. Esteva, M.D., Ph.D.						
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) The University of Texas M.D. Anderson Cancer Center Houston, Texas 77030			8. PERFORMING ORGANIZATION REPORT NUMBER			
<i>E-Mail:</i> festeva@mdanderson.org						
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING / MONITORING AGENCY REPORT NUMBER			
11. SUPPLEMENTARY NOTES						
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited						12b. DISTRIBUTION CODE
13. ABSTRACT (Maximum 200 Words) The purpose of our proposed work is to study differences in serum protein expression profiles between healthy women and women with breast cancer, and to discover novel tumor markers. We intend to generate proteomics spectra on serum samples from 100 healthy women and 100 breast cancer patients. The goal of this analysis is to identify serum proteomic patterns using a matrix-assisted laser desorption ionisation that can distinguish women with breast cancer from healthy women. The origin and full identity of the discriminating proteins or peptides will be investigated. The protocol is under review by the Office of Regulatory Compliance and Quality at U.S. Army Medical Research and Materiel Command. I received their first review of the protocol and informed consent on January 21, 2004, and replied to their comments and concerns on January 30, 2004. I received a second review with additional comments on June 1, 2004 and I replied on June 10, 2004. I am still waiting for the final approval of the protocol and informed consent. I was informed that I can't initiate this study until I receive approval through the USAMRAA Contracting Office. Therefore, I have no results to report at the present time.						
14. SUBJECT TERMS Breast neoplasms, proteomics, serum, tumor markers biological						15. NUMBER OF PAGES 4
						16. PRICE CODE
17. SECURITY CLASSIFICATION OF REPORT Unclassified		18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified		19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified		20. LIMITATION OF ABSTRACT Unlimited

Table of Contents

Cover.....	1
SF 298.....	2
Table of Contents.....	3
Introduction.....	4
Body.....	4
Key Research Accomplishments.....	4
Reportable Outcomes.....	4
Conclusions.....	4
References.....	4
Appendices.....	

Introduction

The purpose of our proposed work is to study differences in serum protein expression profiles between healthy women and women with breast cancer, and to discover novel tumor markers. We intend to generate proteomics spectra on serum samples from 100 healthy women and 100 breast cancer patients. The goal of this analysis is to identify serum proteomic patterns using a matrix-assisted laser desorption ionisation that can distinguish women with breast cancer from healthy women. The origin and full identity of the discriminating proteins or peptides will be investigated.

Body

The protocol is under review by the Office of Regulatory Compliance and Quality at U.S. Army Medical Research and Materiel Command. I received their first review of the protocol and informed consent on January 21, 2004, and replied to their comments and concerns on January 30, 2004. I received a second review with additional comments on June 1, 2004 and I replied on June 10, 2004.

Key Research Accomplishments

N/A

Reportable Outcomes

N/A

Conclusions

We are awaiting the final approval of the protocol and informed consent by the Office of Regulatory Compliance and Quality at U.S. Army Medical Research and Materiel Command. I was informed that I can't initiate this study until I receive approval through the USAMRAA Contracting Office. Therefore, I have no results to report at the present time.

References

N/A